Hjem › Tripelnegativ brystkreft › Oregon › Portland
Kliniske studier for Tripelnegativ brystkreft i Portland, OR
9 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Portland (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- Oregon Health & Science University (OHSU), Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, Portland
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruttererFase 3
- Providence Portland Medical Center ( Site 0116), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0126), Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
RekruttererFase 2
- Providence Portland Cancer Institute - Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Oregon Health & Science University, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Compass Oncology - Rose Quarter, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- Oregon Health & Science Institute (OHSU), Portland
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Portland
- Ikke-småcellet lungekreft46 studier
- Kreft (alle typer)34 studier
- Brystkreft33 studier
- Prostatakreft33 studier
- Metastatisk kreft29 studier
- Kolorektal kreft28 studier
- Eggstokkreft27 studier
- Lungekreft26 studier
- Akut myelogen leukemi25 studier
- Endometriekreft24 studier
- Plateepitelcancer i hode og hals19 studier
- Pankreaskreft19 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.